Format

Send to

Choose Destination
Indian Heart J. 2018 Jul;70 Suppl 1:S96-S101. doi: 10.1016/j.ihj.2018.03.001. Epub 2018 Mar 3.

ST2: Current status.

Author information

1
Department of Cardiology, Sakra World Hospital, Bangalore, India; Cardiology, Apollo Main Hospital, Chennai, India. Electronic address: aditi.dattagupta@sakraworldhospital.com.
2
Department of Cardiology, Apollo Main Hospital, Chennai 600006, India. Electronic address: drsathyamurthy_i@apollohospitals.com.

Abstract

Cardiovascular diseases are leading cause of mortality and morbidity, and are responsible for 1 out of every 6 deaths in the United States.1 Cardiac remodeling is an important determinant of long term outcomes and occurrence of heart failure (HF). Many times one requires additional tools like biomarkers to identify high risk individuals, to diagnose disease conditions accurately and to effectively prognosticate the patients. ST2 is a member of the interleukin 1 receptor family and exists in two forms, a trans-membrane receptor (ST2L) as well as a soluble decoy receptor (sST2).2 The ligand of ST2 is Interleukin-33 (IL-33), which is involved in reducing fibrosis and hypertrophy in mechanically strained tissues.3.

PMID:
30122246
PMCID:
PMC6097168
[Available on 2019-07-01]
DOI:
10.1016/j.ihj.2018.03.001
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center